NCT04201470View on ClinicalTrials.gov

Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

May 23, 2022

Study Completion Date

May 23, 2022

Conditions
Relapsing Remitting Multiple SclerosisProgressive Multiple SclerosisControlsMultiple Sclerosis
Interventions
OTHER

Blood withdrawal

Measurement of serum neurofilaments light chain and GFAP

OTHER

MRI

Cervical and cerebral MRI without contrast injection

OTHER

Neurologic / neuropsychologic tests - Patients

EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)

OTHER

Neurologic / neuropsychologic tests - Controls

NHPT, T25FW, CSCT

Trial Locations (1)

34000

CHU Montpellier, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT04201470 - Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis | Biotech Hunter | Biotech Hunter